缬沙坦分别联合氨氯地平与氢氯噻嗪治疗高血压患者的疗效比较

徐冬梅; 龚正; 丁兆生

doi:10.7619/jcmp.20220186

缬沙坦分别联合氨氯地平与氢氯噻嗪治疗高血压患者的疗效比较

江苏省荣军医院, 江苏无锡, 214035

详细信息

中图分类号: R569;R544
计量
- 文章访问数: 0106
- HTML全文浏览量: 096
- PDF下载量: 010
出版历程
- 收稿日期: 2022-01-13
- 网络出版日期: 2022-05-24

Valsartan combined with amlodipine versus valsartan combined with hydrochlorothiazide in treatment of patients with hypertension

Jiangsu Provincial Rongjun Hospital, Wuxi, Jiangsu, 214035

摘要

摘要:
目的
比较缬沙坦分别联合氨氯地平及氢氯噻嗪治疗高血压的疗效与安全性。
方法
将老年高血压患者120例随机分为观察组与对照组, 观察组采用缬沙坦联合氨氯地平, 对照组采用缬沙坦联合氢氯噻嗪。比较2组患者治疗前后24 h血压水平变化以及一氧化氮(NO)、内皮素(ET)的变化, 观察2组的血压达标及药物不良反应情况。
结果
2组治疗前24 h收缩压、舒张压差异无统计学意义(P>0.05);观察组治疗后24 h收缩压(126.5±8.9) mmHg, 低于对照组的(134.8±9.1) mmHg, 差异有统计学意义(P < 0.05);治疗后观察组和对照组血压达标率分别为95.0%、93.3%;治疗后观察组和对照组患者的NO分别为(69.6±18.7)、(65.4±15.2)μmol/L, 均高于本组治疗前的(27.5±13.5)、(27.6±13.4)μmol/L; ET分别为(33.2±4.5)、(37.1±5.4) ng/L, 均低于本组治疗前的(45.5±8.2)、(45.8±8.4) ng/L; 观察组治疗后血清NO高于对照组, ET低于对照组, 差异均有统计学意义(P < 0.05);治疗后观察组不良反应总发生率为8.3%, 低于对照组的16.7%, 差异有统计学意义(P < 0.05)。
结论
缬沙坦联合氨氯地平能更有效地控制老年高血压患者的收缩压, 提高血清NO水平, 降低ET水平, 保护血管内皮功能。
- 缬沙坦 /
- 氨氯地平 /
- 氢氯噻嗪 /
- 高血压 /
- 一氧化氮 /
- 内皮素
Abstract:
Objective
To compare the efficacy and safety of valsartan combined with amlodipine and valsartan combined with hydrochlorothiazide in the treatment of patients with hypertension.
Methods
A total of 120 eldely patients with hypertension were randomly divided into observation group and control group.The observation group was treated with valsartan and amlodipine, while the control group was treated with valsartan and hydrochlorothiazide.The changes of 24 h blood pressure, nitric oxide (NO) and endothelin (ET) before and after treatment were compared between the two groups, and the condition of blood pressure reaching standard and adverse reactions of drugs were observed in both groups.
Results
There were no significant differences in 24 h systolic blood pressure and diastolic blood pressure before treatment between the two groups (P>0.05);the 24 h systolic blood pressure after treatment in the observation group was (126.5±8.9) mmHg, which was significantly lower than (134.8±9.1) mmHg in the control group (P < 0.05).After treatment, the rates of blood pressure reaching standard in the observation group and the control group were 95.0% and 93.0% respectively.After treatment, the NO levels in the observation group and the control group were (69.6±18.7) and (65.4±15.2)μmol/L respectively, which were significantly higher than (27.5±13.5) and (27.6±13.4)μmol/L before treatment in both groups (P < 0.05);the ET levels were (33.2±4.5) and (37.1±5.4) ng/L in the observation group and the control group, which were significantly lower than (45.5±8.2) and (45.8±8.4) ng/L before treatment in both groups (P < 0.05);serum NO level after treatment in the observation group was significantly higher than that in the control group, and ET was significantly lower than that in the control group (P < 0.05).After treatment, the total incidence rate of adverse reactions in the observation group was 8.3%, which was significantly lower than 16.7% in the control group (P < 0.05).
Conclusion
For elderly patients with hypertension, valsartan combined with amlodipine can more effectively control systolic blood pressure, increase serum NO level, reduce ET level and protect vascular endothelial function.
- valsartan /
- amlodipine /
- hydrochlorothiazide /
- hypertension /
- nitric oxide /
- endotheli

HTML全文

表 1 2组临床疗效比较(x±s)[n(%)]

组别	24 h收缩压/mmHg		24 h舒张压/mmHg		治疗后血压达标
组别	治疗前	治疗后	治疗前	治疗后	治疗后血压达标
对照组(n=60)	157.3±10.0	134.8±9.1^*	100.4±7.6	80.7±6.5^*	56(93.3)
观察组(n=60)	156.5±9.8	126.5±8.9^*#	99.6±7.5	79.6±6.4^*	57(95.0)
与治疗前比较, * P < 0.05; 与对照组比较, #P < 0.05。

下载: 导出CSV

表 2 2组血清一氧化氮、内皮素变化(x±s)

组别	一氧化氮/(μmol/L)		内皮素/(ng/L)
组别	治疗前	治疗后	治疗前	治疗后
对照组(n=60)	27.6±13.4	65.4±15.2^*	45.8±8.4	37.1±5.4^*
观察组(n=60)	27.5±13.5	69.6±18.7^*#	45.5±8.2	33.2±4.5^*#
与治疗前比较, * P < 0.05; 与对照组比较, #P < 0.05。

下载: 导出CSV

表 3 2组不良反应比较[n(%)]

组别	头晕头痛	皮疹	腹胀腹泻	水肿	低钾低钠	合计
对照组(n=60)	2(3.3)	1(1.7)	1(1.7)	1(1.7)	5(8.3)	10(16.7)
观察组(n=60)	1(1.7)	1(1.7)	1(1.7)	1(1.7)	1(1.7)	5(8.3)^*
与对照组比较, * P < 0.05。

下载: 导出CSV

参考文献(22)

[1]	徐春红, 刘玉爽, 焦春颜. 强化健康管理对高血压患者血压及生存质量的影响[J]. 实用临床医药杂志, 2020, 24(18): 68-70. https://www.cnki.com.cn/Article/CJFDTOTAL-XYZL202018021.htm
[2]	刘刚, 王艳. 缬沙坦联合苯磺酸氨氯地平与氢氯噻嗪对高血压伴阵发性房颤患者心功能及血清炎性因子水平的影响[J]. 医学临床研究, 2018, 35(10): 2026-2028. doi: 10.3969/j.issn.1671-7171.2018.10.056
[3]	严华, 郭芳云. 缬沙坦联合氨氯地平治疗老年高血压的临床效果[J]. 临床医学研究与实践, 2021, 6(4): 70-72. https://www.cnki.com.cn/Article/CJFDTOTAL-YLYS202104025.htm
[4]	王雪燕, 张庆考. 氨氯地平单药与氨氯地平联合缬沙坦治疗高危高血压患者的疗效比较[J]. 实用临床医药杂志, 2016, 20(23): 122-124. https://www.cnki.com.cn/Article/CJFDTOTAL-XYZL201623042.htm
[5]	WANG X O, TIAN W. Efficacy of amlodipine besylate and Valsartan for the treatment of mild to moderate hypertension[J]. Medicine, 2019, 98(26): e16264. doi: 10.1097/MD.0000000000016264
[6]	KHAN K M, IQTADAR S, NASIR M, et al. Amlodipine/valsartan (avsar): efficacy in hypertensive patients. A real world observational study (ALERT)[J]. Cureus, 2020, 12(5): e8174.
[7]	JIN X, KIM M H, HAN K H, et al. Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia[J]. J Clin Hypertens (Greenwich), 2020, 22(10): 1835-1845. doi: 10.1111/jch.13893
[8]	《中国高血压防治指南》修订委员会. 中国高血压防治指南2018年修订版[J]. 心脑血管病防治, 2019, 19(1): 1-44. https://www.cnki.com.cn/Article/CJFDTOTAL-XIXG201901003.htm
[9]	DELAVAR F, PASHAEYPOOR S, NEGARANDEH R. The effects of self-management education tailored to health literacy on medication adherence and blood pressure control among elderly people with primary hypertension: a randomized controlled trial[J]. Patient Educ Couns, 2020, 103(2): 336-342. doi: 10.1016/j.pec.2019.08.028
[10]	IDDRISU M A, SENADJKI A, MOHD S, et al. The impact of HPB on elderly diseases (diabetes mellitus, hypertension, hypercholesterolemia, minor stroke, kidney failure and heart problem): a logistic analysis[J]. Ageing Int, 2020, 45(2): 149-180.
[11]	李稳, 李刚. 《老年高血压的诊断与治疗中国专家共识(2017版)》要点介绍[J]. 中华高血压杂志, 2018, 26(10): 986-989. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGGZ201810027.htm
[12]	李静, 范利, 华琦, 等. 中国老年高血压管理指南2019[J]. 中华高血压杂志, 2019, 27(2): 111-135. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGGZ201902010.htm
[13]	陈鲁原, 卢新政. 单片复方制剂降压治疗中国专家共识[J]. 中华高血压杂志, 2019, 27(4): 310-317. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGGZ201904006.htm
[14]	李占华, 李孛. 苯磺酸氨氯地平片联合缬沙坦氢氯噻嗪片治疗中青年2级高血压临床观察[J]. 空军医学杂志, 2020, 36(3): 248-250. https://www.cnki.com.cn/Article/CJFDTOTAL-ZJZY202003019.htm
[15]	赵建霞. 苯磺酸左旋氨氯地平、缬沙坦联合吲达帕胺治疗顽固性高血压的临床效果分析[J]. 海峡药学, 2019, 31(11): 168-169. https://www.cnki.com.cn/Article/CJFDTOTAL-HAIX201911067.htm
[16]	钱晋, 谈世进. 缬沙坦联合氨氯地平或氢氯噻嗪对老年高血压患者血压变异性的影响[J]. 老年医学与保健, 2015, 21(2): 112-114, 129. https://www.cnki.com.cn/Article/CJFDTOTAL-LYBJ201502015.htm
[17]	夏碧荣, 公振宇. 缬沙坦联合氨氯地平与缬沙坦联合氢氯噻嗪治疗老年高血压患者的效果研究[J]. 中国社区医师, 2021, 37(9): 61-62. https://www.cnki.com.cn/Article/CJFDTOTAL-XCYS202109030.htm
[18]	高强. 缬沙坦分别联合氨氯地平、氢氯噻嗪治疗老年性高血压效果比较[J]. 临床合理用药杂志, 2020, 13(2): 49-50. https://www.cnki.com.cn/Article/CJFDTOTAL-PLHY202002026.htm
[19]	姚娬斌. 缬沙坦氨氯地平用于维持性血液透析伴高血压患者血压调控的临床效果[J]. 临床合理用药杂志, 2021, 14(5): 63-65. https://www.cnki.com.cn/Article/CJFDTOTAL-PLHY202105025.htm
[20]	杨静, 李钰兰. 缬沙坦氨氯地平片联合阿托伐他汀钙片治疗高血压伴高血脂的临床效果及其对血管与心肌的保护作用[J]. 中国慢性病预防与控制, 2017, 25(3): 224-226. https://www.cnki.com.cn/Article/CJFDTOTAL-ZMXB201703019.htm
[21]	李劲鸿, 王红. 缬沙坦氨氯地平片联合α-硫辛酸治疗老年2型糖尿病肾病合并高血压的效果及安全性[J]. 昆明医科大学学报, 2021, 42(4): 53-56. https://www.cnki.com.cn/Article/CJFDTOTAL-KMYX202104010.htm
[22]	魏永平, 曾翠连, 叶定村, 等. 缬沙坦与苯磺酸氨氯地平治疗高血压的总有效率及不良反应发生情况分析[J]. 河北医药, 2017, 39(7): 1023-1025. https://www.cnki.com.cn/Article/CJFDTOTAL-HBYZ201707018.htm